Skip to content
Edition of Tuesday, 17 November 2026English edition
The Geopolitician

Country risk, from the local press

China · Country watch

HK Digital Shares, Nvidia's Revenue Surge, CAR T-Cell Coverage

Hong Kong transitions to a digital share market; Nvidia's revenue doubles amid leadership changes; China's insurance to cover CAR T-cell therapy.

The picture Improving How this is judged →

Business conditions in China are improving with Hong Kong's shift to a digital share market and Nvidia's strong financial performance. These developments signal technological advancement and market confidence.

In this briefing Beijing Sinotau International Pharmaceutical Technology · Hong Kong Stock Exchange · CAR T-cell therapy · China's basic insurance · Jensen Huang · Nvidia

Regulation

  • Finance
  • Technology

Hong Kong shifts to fully digitalised share market

The Stock Exchange of Hong Kong Limited, Trade Lobby
The Stock Exchange of Hong Kong Limited, Trade Lobby — WiNG, CC BY-SA 3.0 via Wikimedia Commons

Hong Kong has begun its transition to a fully digitalised share market, with Beijing Sinotau International Pharmaceutical Technology set to be the first IPO without physical share certificates, ChinaMorningPost reports. The plan, spanning five years, includes existing firms like the city's bourse operator transitioning to the new system. This move aims to streamline operations and reduce costs associated with physical certificates. The shift is part of a broader effort to modernize Hong Kong's financial infrastructure and enhance its competitiveness as a global financial hub.

Impact Investors and financial institutions in Hong Kong will experience reduced costs and increased efficiency with the digitalisation of share transactions.

Sources: ChinaMorningPost ↗

  • Pharma
  • Public sector

China's insurance to cover CAR T-Cell therapy from Jan 1

China's basic insurance will begin covering CAR T-cell cancer therapy from January 1, according to Sixth Tone. This therapy involves modifying a patient's cells to combat blood cancer and will be eligible for partial reimbursement. The inclusion of this advanced treatment in the insurance scheme marks a significant step in making cutting-edge medical therapies more accessible to the Chinese population.

Impact Pharmaceutical companies and healthcare providers in China will see increased demand for CAR T-cell therapies with insurance coverage.

Sources: Sixth Tone ↗

Companies

  • Technology
  • Finance

Nvidia revenue doubles, CEO Huang's return ruled out

Part of: Nvidia CEO Huang's affair triggers board investigation →

Nvidia reported a doubling of its third-quarter revenue to over US$115 billion, while ruling out the return of ousted CEO Jensen Huang, according to ChinaMorningPost. This comes amid a Chinese spy scandal involving Huang. The company's strong performance is attributed to its role in the AI boom, which has driven market growth. Nvidia's financial results exceeded expectations, reinforcing its position as a leading player in the semiconductor industry.

Impact Technology investors and market analysts gain confidence from Nvidia's robust financial performance despite leadership changes.

Sources: ChinaMorningPost ↗

Nothing significant reported today in Disruption · Internal tension · Safety & health · Markets · Trade · Politics.

Also today in the local press

Sources in this briefing

Sources: each headline links to the original article on the publisher's site.

All China briefings →